Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

43 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The impact and importance of achieving a complete haematological response prior to renal transplantation in AL amyloidosis.
Cohen OC, Law S, Lachmann HJ, Sharpley F, Ravichandran S, Mahmood S, Sachchithanantham S, Whelan CJ, De Azcona Naharro AM, Fontana M, Hawkins PN, Gillmore JD, Wechalekar AD. Cohen OC, et al. Blood Cancer J. 2020 May 22;10(5):60. doi: 10.1038/s41408-020-0325-2. Blood Cancer J. 2020. PMID: 32444621 Free PMC article. No abstract available.
Use of ixazomib, lenalidomide and dexamethasone in patients with relapsed amyloid light-chain amyloidosis.
Cohen OC, Sharpley F, Gillmore JD, Lachmann HJ, Sachchithanantham S, Mahmood S, Fontana M, Whelan CJ, Martinez-Naharro A, Kyriakou C, Rabin N, Popat R, Yong K, Cheesman S, Shah R, Hawkins PN, Wechalekar AD. Cohen OC, et al. Br J Haematol. 2020 May;189(4):643-649. doi: 10.1111/bjh.16401. Epub 2020 Jan 26. Br J Haematol. 2020. PMID: 31984481 Free article.
Systemic amyloidosis: moving into the spotlight.
Cohen OC, Wechalekar AD. Cohen OC, et al. Leukemia. 2020 May;34(5):1215-1228. doi: 10.1038/s41375-020-0802-4. Epub 2020 Apr 9. Leukemia. 2020. PMID: 32269317 Review.
Rapid response to single agent daratumumab is associated with improved progression-free survival in relapsed/refractory AL amyloidosis.
Cohen OC, Brodermann MH, Blakeney IJ, Mahmood S, Sachchithanantham S, Ravichandran S, Law S, Lachmann HJ, Whelan CJ, Popat R, Rabin N, Yong K, Kyriakou C, Shah R, Cheesman S, Worthington S, Hawkins P, Gillmore JD, Wechalekar AD. Cohen OC, et al. Amyloid. 2020 Sep;27(3):200-205. doi: 10.1080/13506129.2020.1765768. Epub 2020 May 15. Amyloid. 2020. PMID: 32408823 Clinical Trial.
Disease progression in cardiac transthyretin amyloidosis is indicated by serial calculation of National Amyloidosis Centre transthyretin amyloidosis stage.
Law S, Petrie A, Chacko L, Cohen OC, Ravichandran S, Gilbertson JA, Rowczenio D, Wechalekar A, Martinez-Naharro A, Lachmann HJ, Whelan CJ, Hutt DF, Hawkins PN, Fontana M, Gillmore JD. Law S, et al. Among authors: cohen oc. ESC Heart Fail. 2020 Dec;7(6):3942-3949. doi: 10.1002/ehf2.12989. Epub 2020 Sep 13. ESC Heart Fail. 2020. PMID: 32924285 Free PMC article.
Long-term safety and efficacy of patisiran for hereditary transthyretin-mediated amyloidosis with polyneuropathy: 12-month results of an open-label extension study.
Adams D, Polydefkis M, González-Duarte A, Wixner J, Kristen AV, Schmidt HH, Berk JL, Losada López IA, Dispenzieri A, Quan D, Conceição IM, Slama MS, Gillmore JD, Kyriakides T, Ajroud-Driss S, Waddington-Cruz M, Mezei MM, Planté-Bordeneuve V, Attarian S, Mauricio E, Brannagan TH 3rd, Ueda M, Aldinc E, Wang JJ, White MT, Vest J, Berber E, Sweetser MT, Coelho T; patisiran Global OLE study group. Adams D, et al. Lancet Neurol. 2021 Jan;20(1):49-59. doi: 10.1016/S1474-4422(20)30368-9. Epub 2020 Nov 16. Lancet Neurol. 2021. PMID: 33212063 Clinical Trial.
Renal transplant outcomes in amyloidosis.
Law S, Cohen O, Lachmann HJ, Rezk T, Gilbertson JA, Rowczenio D, Wechalekar AD, Hawkins PN, Motallebzadeh R, Gillmore JD. Law S, et al. Nephrol Dial Transplant. 2021 Jan 25;36(2):355-365. doi: 10.1093/ndt/gfaa293. Nephrol Dial Transplant. 2021. PMID: 33439995
Autologous stem cell transplantation vs bortezomib based chemotheraphy for the first-line treatment of systemic light chain amyloidosis in the UK.
Sharpley FA, Manwani R, Petrie A, Mahmood S, Sachchithanantham S, Lachmann HJ, Martinez De Azcona Naharro A, Gillmore JD, Whelan CJ, Fontana M, Cohen O, Hawkins PN, Wechalekar AD. Sharpley FA, et al. Eur J Haematol. 2021 Apr;106(4):537-545. doi: 10.1111/ejh.13582. Epub 2021 Jan 27. Eur J Haematol. 2021. PMID: 33460466
43 results